Articles related to Oncology, Surgical

Presented at SABCS 2021, the EMERALD Study of elacastrant and the PHOEBE Trial of pyrotinib showed a better than doubling of 12-month PFS with the first agent, and an improvement in both OS and PFT with the second agent. And the results of the DESTINY-Breast03 study have been called “practice changing.”

This open-label, randomized phase II-III study of 191 patients with locally advanced or metastatic BTC compared triplet therapy of oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), with doublet therapy consisting of cisplatin and gemcitabine (CISGEM). Triplet therapy did not outperform doublet therapy in this study.

Individuals with cancer often have an elevated platelet count at the time of diagnosis. But what, if any, is the relationship? This study of nearly nine million individuals followed over 10 years points to a positive correlation.

Illucix is a preparation kit for gallium-68 PSMA-11 injection, an agent indicated for PET PSMA position tumors in patients with suspected prostate cancer metastasis who are eligible for initial definitive therapy and have suspected cancer recurrence based on elevated PSA levels.

A JAMA Oncology study of nearly 480,000 patients found immune-mediated diseases are associated with a greater risk of cancer at the local and systemic levels. The findings support the role of local and systemic immunoregulation in carcinogenesis and could lead to a new way of viewing immune-mediated diseases.

The authors of this JCO study used a PET-adaptive approach to reduce the need for radiotherapy (RT) in early PET (-) disease and escalate therapy in patients with PET (+) disease. The study reports excellent outcomes for the approach, which allowed omission of radiotherapy in more than three-quarters of patients.